Loading...
Loading...
Hospira, Inc.
,
applauds Sandoz and the U.S. Food and Drug Administration (FDA) on today's FDA
approval of the first biosimilar in the United States. This is a watershed
moment for improving patient access to safe, effective and more affordable
biologic medicines. As a leading global provider of biosimilars, Hospira has
seen first-hand the positive impact of biosimilars in other countries, and we
are a proud participant in these early stages of the development of a pathway
for these medicines in the United States.
Hospira is the only U.S.-based company currently marketing biosimilars in the
highly regulated markets of Europe and Australia, where we have seen
biosimilars decrease the costs of biologics by 20 to 30 percent. This has
allowed European healthcare systems to reduce their healthcare spending, while
at the same time increasing patient access to these important biologic
medicines.
"Biosimilars represent a transformational opportunity to improve patient
access and provide much-needed financial relief to the U.S. healthcare
system," said Sumant Ramachandra, M.D., Ph.D., senior vice president, Research
& Development and Medical & Regulatory Affairs, and chief scientific officer,
Hospira. "This approval is good news for the entire healthcare system and
brings us one step closer to making these important medications available for
the patients who need them.
"With two biosimilar applications currently under review by the U.S. FDA,
Hospira is committed to bringing more affordable biologic medicines to
patients in the United States. We look forward to continuing to partner with
the FDA on the approval pathway for our biosimilars, so that more and more
patients and healthcare providers have access to the benefits of biosimilars,"
continued Ramachandra.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in